Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 1Phase 2/3 1

Status

Not yet recruiting 3Recruiting 2Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 7Observational 1

Sponsor

Conditions

Myasthenia Gravis 8

Interventions

rozanolixizumab 8zilucoplan 7ravulizumab 6fludarabine 5efgartigimod alfa 5Cyclophosphamide 5telitacicept 3Prednisone 3inebilizumab 2Rituximab 2Pyridostigmine Bromide 2tofacitinib 1thymoglobulin 1talquetamab 1remibrutinib 1prednylidene 1iptacopan 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Therapeutics 1Tacrolimus 1Steroids 1Robotic Surgical Procedures 1Psychodrama 1Prednisolone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Myasthenia Gravis × rozanolixizumab × 1 year × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT07570589 2026-05-11

REAL MG PRO

Centre Hospitalier Universitaire de Nice

Not yet recruiting
50 enrolled

Myasthenia Gravis

NCT06149559 2026-05-08

roMyG

UCB Pharma

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT06540144 2026-05-08

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Enrolling by invitation
12 enrolled

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

UCB Pharma

Phase 3 Not yet recruiting
120 enrolled

Myasthenia Gravis

NCT07465289 2026-03-11

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

UCB Pharma

Phase 3 Not yet recruiting
100 enrolled

Myasthenia Gravis

NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡